Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma

Kovac Viljem; Dodic-Fikfak Metoda; Arneric Niko; Dolzan Vita; Franko Alenka

doi:10.1515/raon-2015-0019

Radiology and Oncology (Sep 2015)

Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma

Kovac Viljem,
Dodic-Fikfak Metoda,
Arneric Niko,
Dolzan Vita,
Franko Alenka

Affiliations

Kovac Viljem: Institute of Oncology Ljubljana, Zaloška cesta 2, Ljubljana, Slovenia
Dodic-Fikfak Metoda: Clinical Institute of Occupational Medicine, University Medical Center Ljubljana, Ljubljana, Slovenia
Arneric Niko: Clinical Institute of Occupational Medicine, University Medical Center Ljubljana, Ljubljana, Slovenia
Dolzan Vita: Pharmacogenetics Laboratory, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
Franko Alenka: Clinical Institute of Occupational Medicine, University Medical Center Ljubljana, Ljubljana, Slovenia

DOI: https://doi.org/10.1515/raon-2015-0019
Journal volume & issue: Vol. 49, no. 3
pp. 279 – 285

Abstract

Read online

Background. Fibulin-3 is a new potential biomarker for malignant mesothelioma (MM). This study evaluated the potential applicability of fibulin-3 plasma levels as a biomarker of response to treatment and its prognostic value for progressive disease within 18 months. The potential applicability of fibulin-3 in comparison with or in addition to soluble mesothelin-related peptides (SMRP) was also assessed.

Published in Radiology and Oncology

ISSN: 1581-3207 (Online)
Publisher: Sciendo
Country of publisher: Slovenia
LCC subjects: Medicine: Medicine (General): Medical physics. Medical radiology. Nuclear medicine
Website: https://sciendo.com/journal/RAON

About the journal

Abstract

Keywords